secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001437749-25-014402
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q1 BRIUMVI sales $119.7M (+137% YoY); raises FY revenue guidance
--------------------------------------------------------------------------------

- Q1 2025 BRIUMVI U.S. net revenue $119.7M vs $50.5M YoY, up ~137%.
- Net income $5.1M vs net loss $10.7M in Q1 2024; GAAP improvement.
- Raises FY2025 BRIUMVI U.S. net revenue target to ~$560M (prior $525M).
- Raises FY2025 total global revenue target to ~$575M (prior $540M).
- Q2 2025 BRIUMVI U.S. net revenue target set at $135M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925014402/0001437749-25-014402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925014402/tgtx20250502_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer